The cost of ischaemic stroke in Croatia

Abstract

Objective: The aim of this analysis was to estimate 1 year and long-term cost and quality of life of ischaemic stroke patients in Croatia. In addition, we aimed to identify and estimate key categories of costs and outcomes driving the burden of stroke in Croatian healthcare system. Methods: Data were derived from analysis of the RES-Q Registry for Croatia in 2018 and supplemented with clinical expert opinion and relevant medical, clinical and economic literature to estimate the course of the disease and treatment patterns in Croatian healthcare system. The health economic model was comprised of a one-year discrete event simulation (DES) mapping real life patient experience and a 10-year Markov model built on existing literature. Cost and health resources use were obtained using Croatian tariffs. Health utilities were mapped to EQ5D from the Barthel Index utilising previously published studies. Results: The key aspects determining costs and quality of life were rehabilitation, discharge to residential care (currently 13% of patients in Croatia) and recurrent stroke. Total 1 year cost per patient was 18,221 EUR having 0.372 QALYs. Conclusion: Direct costing structure of ischaemic stroke in Croatia is above the value of upper-middle income countries. Our study showed that post stroke rehabilitation seems to be a strong modifier of future post-stroke costs and further research into various models of post-stroke care and rehabilitation could be the answer into more successful rehabilitation that could increase QALY and reduce the economic burden of stroke. Further investment in rehabilitation research and provision might bring promising opportunities to improve long term patient outcomes.

Crystal Engineering to Solidify and Chemically Stabilize Oily dl-Butylphthalide

“…Stroke killed 6.6 million people in 2019 and has become the leading cause of disability worldwide, resulting in a huge socio-economic burden. − It can be roughly classified into three categories: ischemic stroke, hemorrhagic stroke, and subarachnoid hemorrhage, and therein 60–80% are ischemic stroke . Dl-3- n -Butylphthalide (trade name: NBP) was approved by the State and Drug Administration of China in 2002 for the treatment of ischemic stroke. , It works by ameliorating microcirculation, protecting mitochondrial function, restraining oxidative stress, and inhibiting neuronal apoptosis .…”

Global, Regional, and National Economic Consequences of Stroke

“…1 Despite this body of work, assessments related to the macroeconomic impact of stroke on regional and national economies remain sporadic. [8][9][10] In fact, to the authors' knowledge, no study has yet assessed the macroeconomic consequences of stroke and pertinent subtypes globally in a standardized manner. Given that the absence of such data is known to deter policy priority and attention, 11 such an analyses may ultimately be leveraged to help drive resource allocation, and in so doing, improve stroke patient care globally.…”